Last reviewed · How we verify
NCT06950814
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
trial testing postoperative adjuvant therapy in Sarcomatoid Carcinoma in 50 participants. Currently enrolling.
3 May 2025
Quick facts
| Lead sponsor | West China Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 5 April 2025 |
| Primary completion | 3 May 2025 |
| Estimated completion | 5 May 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- postoperative adjuvant therapy
Conditions studied
- Sarcomatoid Carcinoma — all drugs for Sarcomatoid Carcinoma →
- Liver Cancer — all drugs for Liver Cancer →
- Adjuvant Therapy — all drugs for Adjuvant Therapy →
Sponsor
West China Hospital
Who can join
18 and older, any sex, with Sarcomatoid Carcinoma or Liver Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prognostic impact of adjuvant therapy following surgical resection in primary hepatic sarcomatoid carcinoma: a retrospective cohort study.
Ji J, Hu D, Wang J, Qiu G, et al · · 2025 · cited 2× · PMID 40697077 · DOI 10.1097/js9.0000000000002948
Verify or expand the search:
- PubMed search for NCT06950814
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcomatoid Carcinoma
Currently open trials in the same condition.
- NCT06683846 — Ivonescimab in the Treatment of Multiple Advanced Tumors · Phase 2 · recruiting
Other West China Hospital trials
Trials by the same sponsor.
- NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
- NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06950814 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West China Hospital
- Last refreshed: 30 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06950814.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing